News & Events
1Cell.Ai Completes CLIA Validation Study of OncoIncytes 1080-Gene NGS Panel
FOSTER CITY, Calif., May 28, 2025 /PRNewswire/ — 1Cell.Ai, a precision oncology company developing advanced cell and molecular profiling platforms, announced the successful completion of a CLIA-grade analytical validation study of its OncoIncytes 1080-gene NGS panel and proprietary
2025 ASCO Annual Meeting
1Cell.Ai at ASCO 2025: Explore Our Latest Research We’re excited to share 19 new posters and abstracts at the 2025 ASCO Annual Meeting. Our latest findings highlight the power of single-cell, live-cell, and ctDNA analysis
1Cell.Ai and BioSkryb Announce Strategic Partnership to Advance Single Cell Multi-omics Innovation
FOSTER CITY, Calif. and DURHAM, N.C., April 24, 2025 /PRNewswire/ — 1Cell.Ai, a global leader in single cell precision diagnostics, has joined forces with BioSkryb Genomics, a pioneer in single cell multi-omics, to co-develop and commercialize next-generation single cell multi-omic solutions.
1Cell.Ai, Formerly OneCell Diagnostics, Launches OncoIncytes Integrating Multi-Modal Data for Precision Oncology
AI-powered precision oncology leader to enhance early-stage clinical studies with the introduction of next-generation technology Foster City, CA. & Mumbai, India (April 22, 2025) – OneCell Diagnostics today announced its launch of OncoIncytes, a comprehensive
Single-Cell Genomics Reveals Resistance Signatures in Colorectal Cancer
Presented at ESMO Congress 2024 – Barcelona, Spain This abstract highlights how true single-circulating tumor cell (CTC) genomics can identify enriched therapy-resistance signatures in advanced colorectal cancer patients. The findings underscore the potential of single-cell